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Clinical interest continues to focus on the associ-
ation between homocysteinemia and cardiovascular
BASIC RESEARCH STUDIES
From the Eastern Vascular Society
1121
disease. Since McCully1 proposed the relationship
between elevated homocysteine levels and the pres-
Folic acid inhibits homocysteine-induced
proliferation of human arterial smooth
muscle cells
Brennan J. Carmody, MD, Subodh Arora, MD, Ricardo Avena, MD, Kenyatta
Cosby, BS, and Anton N. Sidawy, MD, Washington, DC
Purpose: An elevated plasma homocysteine level has been identified as an independent
risk factor for atherosclerosis. Whether this represents a marker for vascular disease or a
direct effect on the vasculature remains unclear. Because vascular smooth muscle cells
(VSMCs) play an integral role in the atherosclerotic process, we studied the effect of
homocysteine on human infragenicular VSMC proliferation and the role of folic acid in
reversing the homocysteine effect.
Methods: Human infragenicular VSMCs harvested from amputation specimens were
studied. Various cell groups were exposed to physiologic (6.25 m mol/L and 12.5
m mol/L) and pathologic (25 m mol/L to 500 m mol/L) concentrations of homocysteine.
Similar groups were simultaneously exposed to 20 nmol/L of folic acid. Cell counts and
DNA synthesis, as reflected by [methyl-3H]-thymidine incorporation, were performed
at 6 days and 24 hours, respectively. Additional groups were exposed to various combi-
nations of folic acid (20 nmol/L), vitamin B6 (145 nmol/L), and vitamin B12 (0.45
nmol/L) in the presence of homocysteine (25, 50, and 250 m mol/L).
Results: Homocysteine resulted in a dose-dependent increase in DNA synthesis and cell
proliferation. Cell counts increased significantly at homocysteine concentrations ranging
from 25 m mol/L to 500 m mol/L (P < .05), with a maximal increase of 98% at 500
m mol/L of homocysteine. The addition of 20 nmol/L folic acid resulted in significant
inhibition of cell proliferation at all homocysteine concentrations studied (P < .001).
Maximal inhibition of 70% occurred in the cells exposed to 50 m mol/L of homocysteine.
The increases in [methyl-3H]-thymidine incorporation ranged from 36% at 6 m mol/L
homocysteine to a maximum of 247% at 500 m mol/L homocysteine. All increases were
statistically significant (P < .05). The addition of 20 nmol/L folic acid resulted in sig-
nificant inhibition of DNA synthesis (P < .002). Vitamins B6 and B12 did not demon-
strate significant antiproliferative properties.
Conclusion: A possible role of homocysteine in the formation of atherosclerotic lesions
is through a direct proliferative effect on VSMCs in a dose-dependent fashion. Folic acid
intake at levels available in dietary supplements may prove protective in hyperhomocys-
teinemia-induced atherosclerosis. Vitamins B6 and B12 alone do not appear to exhibit a
substantial inhibitory effect in the setting of elevated homocysteine levels. (J Vasc Surg
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ence of arterial occlusive disease in patients with
homocysteinuria in 1969, it has been shown that
patients with arterial occlusive disease commonly
have elevated plasma levels of homocysteine.2 Even
mild elevations of plasma homocysteine are associat-
ed with vascular complications.2 Recently, hyperho-
mocysteinemia has been identified as an indepen-
dent risk factor for coronary artery disease,3,4
peripheral vascular disease,5,6 and stroke,7,8 and it
has been estimated that 20% to 30% of patients with
premature atherosclerosis exhibit this biochemical
abnormality.9
The exact mechanism by which homocysteine
induces atherosclerotic changes remains unclear.
Homocysteine may act directly on the vasculature,
or elevated levels may merely serve as a marker for
those predisposed to the development of vascular
disease.9-11 Plausible possibilities include endothelial
toxicity, impaired endothelial production of nitric
oxide, enhanced nitric oxide quenching, or vascular
smooth muscle proliferation.10 This latter hypothe-
sis has been studied, and the data suggest that
homocysteine can act directly on vascular smooth
muscle cells (VSMCs) and induce proliferation.9,10
These in vitro studies, however, involved homocys-
teine concentrations infrequently encountered in
clinical practice. Moreover, the role of folic acid, vit-
amin B6, and vitamin B12, which are now known to
decrease plasma homocysteine levels,12 has not been
addressed with in vitro studies.
Because VSMC proliferation plays an integral
role in the atherosclerotic process, we studied the
effect of homocysteine in various concentrations on
human arterial smooth muscle cell proliferation and
whether folic acid and vitamins B6 and B12 would
modulate homocysteine’s effect.
MATERIALS AND METHODS
Harvesting and cell characterization. Segments
of human tibial vessels were obtained at the time of
lower-extremity amputations that were performed for
peripheral vascular disease on five male patients with
diabetes mellitus. Four of the five patients underwent
amputation for treatment of infection, whereas the
remaining patient had chronic peripheral vascular dis-
ease with tissue loss that was treated with amputation.
Some vessels were chronically occluded, whereas other
vessels were patent. The mean age of the patients was
70.8 years. After removal of the vessels from the spec-
imen, the media was mechanically separated immedi-
ately after harvest from other vessel layers, minced, and
allowed to soak in a 0.8% collagenase and 0.05% elas-
tase solution for 2 hours. Cells were centrifuged,
rinsed, and added to a solution containing Medium
199 (Gibco BRL, Grand Island, NY), 10% fetal bovine
serum (FBS; Gibco BRL), and 2% antibiotic-antimy-
cotic (10,000 U/mL penicillin G sodium, 10,000
m g/mL streptomycin sulfate, and 25 m g/mL
Amphotericin B; Gibco BRL) before transfer to a 75
cm2 flask. Cells were cultured at 37°C in a humidified
incubator at 5% CO2. When confluence was achieved,
the cells were trypsinized with 0.25% trypsin-EDTA
(Gibco BRL) and subcultured. The cells used in this
experiment were from passages 2 through 5; they were
combined into one population of cells before being
passed into wells at the beginning of this study.
At passage 1, cells were identified as smooth mus-
cle cells by using a previously described immunohis-
tochemistry technique.13 In brief, the cells were
grown on coverslips at 35,000 cells/mL to subcon-
fluence and incubated overnight with primary anti-
bodies directed against a -smooth muscle actin,
myosin, vimentin, desmin, vitronectin, fibronectin,
and chondroitin sulfate. Fluorescein-tagged sec-
ondary antibodies were added to the cultures, and
cells were later identified with fluorescent light
microscopy.
Proliferative studies and thymidine incorpora-
tion. The VSMCs were pooled into a mixed culture,
grown to subconfluence, and divided into four
groups to examine the effect of varying concentra-
tions of homocysteine on cell proliferation and to see
whether the addition of folic acid modulated this
effect. Group 1 was a control group incubated in
Medium 199, 10% FBS, and 2% antibiotic-antimy-
cotic. Group 2 consisted of cells in an identical medi-
um, with the addition of 20 nmol/L folic acid
(Sigma Chemical, St. Louis, Mo). Group 3 was
divided into six subgroups, each containing a differ-
ent concentration of homocysteine. We sought to use
homocysteine concentrations found in clinical prac-
tice, ranging from normal (12.5 m mol/L or less) to
pathologic (25 to 500 m mol/L). Each subgroup was
exposed to Medium 199, 10% FBS, 2% antibiotic-
antimycotic, and one of six concentrations of d,l-
homocysteine (Sigma): 3a, 6 m mol/L; 3b, 12.5
m mol/L; 3c, 25 m mol/L; 3d, 50 m mol/L; 3e, 250
m mol/L; and 3f, 500 m mol/L. Group 4 was divided
into identical subgroups, and cells were also exposed
to 20 nmol/L folic acid. Smooth muscle prolifera-
tion was measured with two different techniques, cell
count and [methyl-3H]-thymidine incorporation.
For the cell count, VSMCs were seeded in six-
well plates at 5000 cells/mL in 2 mL of fortified
medium and allowed 48 hours for attachment. They
were then exposed to deprived medium for 48 hours
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to achieve quiescence. The different groups of the
VSMCs were exposed to the different concentra-
tions of homocysteine, with or without folic acid, as
described. Cells were counted in triplicate by means
of a standard hemocytometer on day 6.9 Culture
medium, homocysteine, and folic acid were replaced
on days 2 and 4. Values were expressed as the mean
± SEM from six wells for each group.
For the thymidine incorporation technique, the
VSMCs were seeded in 24-well plates at 30,000
cells/well in 1 mL of fortified medium and allowed
to grow to a count of 50,000 cells/well. Cells were
exposed to deprived medium (Medium 199 with 2%
antibiotic-antimycotic) for 48 hours to inhibit fur-
ther growth. The various concentrations of homo-
cysteine with or without folic acid were then added,
as described. VSMCs were incubated at 37°C for 20
hours, at which time [methyl-3H]-thymidine (2
m Ci/well) was added. At the 24-hour mark, the cells
were washed three times with phosphate-buffered
solution (Gibco BRL, Grand Island, NY). The
incorporated [methyl-3H]-thymidine was extracted
with 0.2 N NaOH and precipitated with 10%
trichloroacetic acid before being measured in a liq-
uid scintillation counter. Values were expressed as
the mean percentage ± SEM decays per minute
(DPM), as compared with controls from six wells
from two separate experiments.
To examine the effects of vitamins B6 and B12 on
homocysteine-induced cell proliferation, additional
cell count experiments were performed. VSMCs
were divided into four groups. Group 1 consisted of
three subgroups exposed to 25, 50, or 250 m mol/L
homocysteine. Group 2 cells were exposed to identi-
cal homocysteine concentrations, with the addition
of 145 nmol/L vitamin B6 and 20 nmol/L folic acid.
Group 3 cells were grown in identical homocysteine
concentrations and 0.45 nmol/L vitamin B12 with
20 nmol/L folic acid. Group 4 cells were cultured in
identical homocysteine concentrations with vitamins
B6, B12, and folic acid at the concentrations given
earlier. These experiments were repeated by using
identical homocysteine and vitamin B6 and B12 con-
centrations, but in the absence of folic acid.
Statistical analysis. Statistical analysis was per-
formed with Sigmastat software (Jandel Scientific,
San Rafael, Calif). One-way analysis of variance was
used to compare the results of cell count and thymi-
dine incorporation of the increasing concentrations
of homocysteine to the control group. The Student
t test was used to analyze the effect of folic acid at
each concentration of homocysteine studied.
Statistical significance was identified as P < .05.
RESULTS
Immunohistochemistry. VSMCs showed char-
acteristic cytoskeletal proteins by exhibiting strong
fluorescence of secondary antibodies when primary
antibodies against a -smooth muscle actin, myosin,
vimentin, fibronectin, and chondroitin sulfate were
present (Fig 1). A weak fluorescence pattern resulted
when primary antibodies against desmin and vit-
ronectin were present. Chamber slides in the absence
of primary antibodies demonstrated only an extreme-
ly faint “random” fluorescence, indicating the high
specificity of the secondary antibodies.
Effects of homocysteine and folic acid on cell
proliferation. Homocysteine administration to
smooth muscle cell culture media resulted in a
dose-dependent increase in cell proliferation when
counted on day 6, as illustrated in Fig 2. At physio-
logic concentrations of 6.25 m mol/L and 12.5
m mol/L homocysteine, cell growth was not signifi-
cantly increased when compared with controls. At
pathologic concentrations of homocysteine ranging
from 25 m mol/L to 500 m mol/L, however, signifi-
cant proliferation occurred, the increase ranging
from 36% to 98% (17,083 ± 1074 and 24,931 ±
1391) more than controls (P < .05). The addition
of 20 nmol/L folic acid resulted in inhibition of this
VSMC proliferation. This suppression was noted at
all concentrations of homocysteine, and no signifi-
cant antiproliferative effect was shown in the
absence of homocysteine (group 2). Increasing sup-
pression was seen at higher homocysteine concen-
trations. This inhibition of growth by folic acid was
statistically significant at all homocysteine concen-
trations (P < .001).
Effects of homocysteine and folic acid on
thymidine incorporation. Administration of homo-
cysteine to the culture media resulted in a dose-
dependent increase in DNA synthesis, as illustrated in
Fig 3. Because of the wide variability in [methyl-3H]-
thymidine uptake, depending on the degree of sub-
confluence, groups were compared with the DPM
values obtained in the control group and expressed as
percent change compared with controls. Control
DPM values were considered to be 100. Increases in
uptake ranged from 36% at 6 m mol/L homocysteine
to a maximum of 247% at 500 m mol/L. All increases
were noted to be statistically significant. The addition
of folic acid resulted in inhibition of DNA synthesis at
all concentrations of homocysteine studied. The
decrease in DNA synthesis was statistically significant
at all homocysteine concentrations (P < .002).
Effect of homocysteine and vitamins B6 and
B12 on cell proliferation. When vitamins B6 and
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B12 were administered with folic acid, significant
inhibition of cell proliferation occurred (Fig 4).
Decreases in cell count ranged from 21% (16,705 ±
863 to 13,750 ± 416) by using vitamin B6 and folic
acid in the presence of 25 m mol/L homocysteine to
98% (21,682 ± 550 to 10,903) by using both vita-
mins B6 and B12 with folic acid in cells exposed to
250 m mol/L homocysteine. In addition, in cells
cultured in media containing 25 and 50 m mol/L
homocysteine, the combination of vitamins B6, B12,
and folic acid demonstrated enhanced antiprolifera-
tive effect (23% and 29% reductions in cell count; P
< .05) compared with vitamin B6 and folic acid
alone. When vitamins B6 and B12 were administered
to cells cultured in media containing 25, 50, and
250 m mol/L homocysteine without folic acid, a
diminished antiproliferative effect was evident, as
illustrated in Fig 5. Although statistically insignifi-
cant, vitamins B6 and B12, each alone or combined,
suppressed proliferation in the 25 m mol/L and 50
m mol/L homocysteine groups from 13% to 18%.
However, the combination of the two vitamins was
significantly antiproliferative only at 250 m mol/L
homocysteine, with a 21% reduction in cell count.
DISCUSSION
Homocysteine was found to stimulate human
infragenicular VSMC proliferation in a dose-depen-
dent fashion in the absence of endothelial cells. This
finding supports a direct effect on smooth muscle
cells. Also, folic acid demonstrated a significant
inhibition of this proliferative effect of homocys-
teine at all concentrations studied. These findings
were demonstrated through direct cell count stud-
ies and confirmed with [methyl-3H]-thymidine
incorporation.
Homocysteine is a product of methionine metab-
olism; it can be remethylated to methionine by 5-
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Fig 1. Composite photomicrograph demonstrating immunofluorescent images of secondary
fluorescein isothiocyanate antibodies when primary antibodies against A, a -smooth muscle
actin, B, myosin, and C, vimentin were used. Strong fluorescence of secondary antibodies is
shown when primary antibodies were bound to their specific epitope. D, When no primary
antibody was present, an extremely weak “random” fluorescence was observed with the addi-
tion of secondary antibodies (original magnification, 200· .)
A B
C D
methyltetrahydrofolate homocysteine methyltrans-
ferase, a reaction that requires vitamin B12 as a coen-
zyme, or it can be converted to cysteine through the
transsulfuration pathway, with vitamin B6 acting as a
co-factor.14,15 These enzymatic reactions rely on ade-
quate levels of folic acid, vitamin B12 , and vitamin B6.
Vitamin deficiency thus represents one explanation
for hyperhomocysteinemia. Other etiologies include
homozygosity for cystathionine-b -synthase deficiency
(resulting in homocysteinuria), renal insufficiency,
drugs, and enzyme mutations (heat labile 5,10-
methyltetrahydrofolate reductase).9,14 Vitamin sup-
plementation, primarily folic acid, can significantly
lower plasma homocysteine levels.12,16-18 Folic acid
has been widely studied because of its pivotal role as a
methyl donor in the conversion of homocysteine to
methionine.14,15 In a meta-analysis of 12 randomized
controlled trials involving 1114 patients, folic acid
supplementation reduced plasma homocysteine con-
centrations by 25%.19 Long-term clinical trials are
currently underway to investigate whether such
reductions in homocysteine will likewise decrease the
risk of vascular disease.20,21
Earlier studies have examined the proliferative
effects of homocysteine on VSMCs. Tsai et al9 and
Tang et al10 demonstrated stimulation in rat aortic
and human internal mammary artery VSMCs,
respectively. These investigations were performed
with concentrations of homocysteine ranging from
62.5 m mol/L to 10,000 m mol/L. Even the lowest
of these concentrations is rarely encountered in the
patient with mild to moderate hyperhomocysteine-
mia. Within this range of mild to moderate hyper-
homocysteinemia (14 to 25 m mol/L), the most
interest and potential for clinical benefit lie. This
study allowed cells to be exposed to physiologic and
pathologic homocysteine concentrations in the pres-
ence of 10% FBS. This culture medium contains
multiple growth factors and more closely mimics an
in vivo setting. This is especially important in this
study, because approximately 80% of homocysteine
in the human body is bound to serum proteins.
Media containing lesser amounts of protein allow
cells to be exposed to higher concentrations of
unbound homocysteine at any given dose.10 Our
experimental model more closely resembles the in
vivo setting. Homocysteine induced significant pro-
liferation of VSMCs at concentrations ranging from
25 m mol/L to 500 m mol/L. These concentrations
of homocysteine have been previously identified as
being pathologic and associated with vascular disease
in humans in the clinical setting.18,22,23 The two
homocysteine concentrations at the lower end of the
spectrum used in our experiment, 6.25 m mol/L and
12.5 m mol/L, were not associated with significant
VSMC proliferation. This finding again correlates
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Fig 2. Effects of homocysteine and folic acid on cell pro-
liferation at 6 days. *, P < .05 compared with control; +,
P < .05 compared to the same concentration of homocys-
teine in the presence of folic acid; Hcy, homocysteine.
Fig 3. Effects of homocysteine and folic acid on 3H-
thymidine incorporation after 24 hours of incubation. *, P
< .05 compared with control; +, P < .05 compared to the
same concentration of homocysteine in the presence of
folic acid; Hcy, homocysteine.
with the clinical setting, because these concentra-
tions fall within the accepted normal range for
homocysteine. At the concentrations involved in this
study, homocysteine may interact with growth fac-
tors, cytokines, or both to exert its proliferative
effect on smooth muscle cells. This effect may be
modulated in part in vivo by macrophage secretion
of such growth factors. Arterial wall smooth muscle
cells can come in contact with homocysteine found
in blood via various routes. Because homocysteine 
is toxic to endothelial cells, intimal VSMCs can 
be exposed to intraluminal homocysteine after
endothelial damage. In addition, medial VSMCs are
exposed to homocysteine found in serum via the
vasa vasora that supply the arterial wall with blood.
Therefore, the VSMC milieu is exposed to the same
homocysteine concentration found in blood. These
cells were harvested from male patients with diabetes
mellitus who had peripheral vascular disease. The
factors may have increased the VSMC sensitivity to
homocysteine, but folic acid still inhibited the
homocysteine effect in these cells.
Equally exciting is the antiproliferative effect of
folic acid. Its ability to lower serum homocysteine
levels has been documented,12,18,19 along with the
relationship between low folic acid levels, elevated
homocysteine concentrations, and cardiovascular
morbidity.23-25 The nature of the benefit concurred
by means of folic acid supplementation remains ill-
defined. This study does not support a direct effect
of folic acid on VSMCs, and its protective effect may
be mediated by its ability to lower homocysteine lev-
els. The exact mechanism of folic acid’s antiprolifer-
ative action, however, remains unclear. The folic acid
concentration (20 nmol/L) used was based on data
from several investigators.22,26 Not only is this level
clinically relevant, but it can also be achieved with
dietary supplementation. Further studies with
increased doses of folic acid might elucidate whether
higher folic acid levels have an improved antiprolif-
erative effect. Folic acid appears to be a more potent
antiproliferative agent than vitamins B6 and B12.
Our data demonstrate that vitamins B6 and B12 have
minimal inhibitory action on VSMCs exposed to
elevated homocysteine levels.
Although our data indicate that homocysteine
stimulates proliferation in VSMCs, other investigators
have observed inhibition of endothelial cell growth in
a dose-dependent fashion,9 indicating a toxic effect
toward endothelial cells. These data offer a possible
explanation of homocysteine’s role in atherosclerosis:
It injures endothelial cells, while stimulating the pro-
liferation of VSMCs, thus causing atherosclerosis.
Because we have shown that folic acid inhibits homo-
JOURNAL OF VASCULAR SURGERY
1126 Carmody et al December 1999
Fig 4. Effects of folic acid/vitamins B6 and B12 combi-
nations on homocysteine-induced cell proliferation at 6
days. Vitamins B6 and B12 did not alter cell proliferation
significantly from the effect observed with folic acid alone.
*, P < .05 compared to same homocysteine concentration
without added folic acid or vitamins; H, homocysteine;
FA, folic acid; B6, vitamin B6; B12, vitamin B12.
Fig 5. Effects of folic acid or vitamins B6 and B12 on homo-
cysteine-induced cell proliferation after 24 hours of incuba-
tion. *, P < .05 compared to same homocysteine concentra-
tion without added folic acid or vitamins; H, homocysteine;
FA, folic acid; B6, vitamin B6; B12, vitamin B12.
cysteine-induced VSMC proliferation at doses that
can be achieved with oral intake, folic acid at levels
available in dietary supplements may prove protective
in hyperhomocysteinemia-induced atherosclerosis.
The authors would like to acknowledge the expert
advice of James Finkelstein, MD, during the planning and
execution of this study.
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Dr K. Craig Kent (New York, NY). I’d like to congrat-
ulate Tony and his group for their excellent work and their
many continued contributions to vascular biology. One of
the exciting aspects of this group’s work is the use of
smooth muscle cells that are derived from the tibial vessels
of patients with peripheral vascular disease. By using these
types of cells, their findings are made particularly relevant.
Today, we’ve gained insight into the relationship
between homocysteine and peripheral vascular disease.
We’ve learned that homocysteine is not just a marker for
DISCUSSION
vascular disease, but this molecule stimulates the patho-
logic events that lead to the development of atherosclero-
sis. Levels of homocysteine equivalent to those found in
patients have a profound stimulatory effect on smooth
muscle cell proliferation. Even more interestingly, folic
acid, which in vivo is known to reduce levels of homocys-
teine, is able to reverse this stimulatory effect.
I have several questions.
First, are smooth muscle cells actually exposed to
homocysteine in vivo? Endothelial cells are obviously in
contact with homocysteine, because these cells line the
luminal surface of blood vessels. However, in the early
phases of atherosclerosis the endothelial layer is intact.
How do smooth muscles contact homocysteine?
Second, does homocysteine have other pathologic
effects on smooth muscle cells? Does it stimulate smooth
muscle cell migration or the elaboration of extracellular
matrix protein, or is its only pathologic effect through
smooth muscle cell proliferation?
Next, I have a technical question. When you evaluat-
ed the proliferation with cell counts, you used raw data for
your comparison. When you evaluated DNA synthesis,
you had to display your results as a percent increase over
the control, because of significant variability in the data.
Why was it necessary to use two different approaches in
analyzing your data?
Finally, can you speculate about the mechanism by
which folic acid reverses the stimulatory effect of homo-
cysteine on DNA synthesis? In vivo folic acid enhances the
conversion of homocysteine to another metabolite, and,
thus, homocysteine levels are diminished. Have you mea-
sured homocysteine levels in your cells? Are they reduced?
Is it possible that folic acid could more directly affect
smooth muscle cells, independently of homocysteine?
I enjoyed this work. It is excellent. I encourage you to
continue these investigations, and I thank you for the
opportunity to discuss this paper.
Dr Brennan J. Carmody. Thank you, Dr Kent, for
your insightful questions.
To answer your first question, homocysteine has been
shown by several investigators to damage the endothelium
itself also, resulting in decreased proliferation and a direct
toxic effect. After endothelial injury, the media itself may
be exposed, and smooth muscle cells then may be exposed
directly to homocysteine. Also, the homocysteine in the
blood, which goes through the vasa vasorum and reaches
the media that way, bypasses the endothelium to some
degree and may allow a more direct route to the vascular
smooth muscle cell itself.
To answer your second question regarding other
pathologic changes in the vascular smooth muscle cell
relating to homocysteine, we have not studied prolifera-
tion or matrix protein production. And as far as I know, no
other studies on smooth muscles cells have looked at this.
One study from Australia has looked at certain genes,
which are being expressed, namely the cyclin genes, which
are regulators of cell regulation. And these are the only
studies focusing on particular gene expression that I know
of at this time.
To answer the technical question regarding our using
percent for our DNA synthesis results and cell count for our
proliferation results, with thymidine incorporation, we had
to do these experiments in batches because of the several
groups within the study and the scintillation machine that we
used. So, variations in cell count and the age of the thymi-
dine would produce variations in the counts per minute and
would make integrating these different batches almost
impossible for giving good results. So, we went ahead and
standardized them to each control for each batch.
As far as the folic acid effect, what is really responsible
for the antiproliferation, a direct effect on the smooth mus-
cle cell or the homocysteine lowering effect? We believe
that folic acid, which lowers the homocysteine concentra-
tion, is responsible for the antiproliferative effect.
We did not measure homocysteine directly from our
cell media, which would answer the question, is this being
taken up by the vascular smooth muscle cell and metabo-
lized? Other investigators, Tang and colleagues from
Australia, did measure media homocysteine levels and
found that after 24 hours the amount of homocysteine in
the media had gone down to 49% of the original value at
time zero. So, available data suggest that homocysteine is
being taken into the cell and that the folic acid is reducing
the homocysteine within the vascular smooth muscle cell.
At the Washington Veterans Administration Hospital,
we have the privilege to have Dr James Finkelstein, who is
very familiar with homocysteine and the enzymes respon-
sible for its metabolism and the metabolism of other sul-
fur-containing amino acids, on staff. He believes that these
tissues that we’re using have the enzymatic capabilities to
metabolize homocysteine. And with the addition of folic
acid, we think that we are lowering the homocysteine con-
centration.
Dr Prasad Gade (Brooklyn, NY). I congratulate the
authors for an elegant study. I have a couple of questions.
You studied smooth muscle cells that were isolated
from amputation stumps. Did you look at smooth muscle
cells isolated from the healthy vessels? And is there any dif-
ferential response between the healthy smooth muscle
cells and the smooth muscle cells isolated from the dis-
eased tibial vessels?
Does homocysteine have a proliferative effect on
endothelial cells? If that is the case, actually it will help pre-
vent atherosclerosis.
Dr Carmody. Thank you. We only performed our
studies on tissues obtained from amputation, so we used
cells from diseased vessels. These all had extensive plaques.
Some were completely or nearly occluded. However, we
were not using necrotic tissue. So, we used tissue that was
present in atherosclerotic vessels. We have not taken
smooth vessels cells from healthy vessels, so we’re unable
to make that comparison.
Your other question was on endothelial cells. Other
investigators have shown an opposite, a reverse, effect on
endothelial cells, an inhibition of proliferation and an inhi-
bition of DNA synthesis. So, it sets up a paradigm of
endothelial damage that allows smooth muscle cell expo-
sure and proliferation.
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